MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2

Reuters
Sep 22
MIRA Pharmaceuticals Announces Promising Topline Results from Phase 1 Study of Novel Oral Therapeutic Ketamir-2

MIRA Pharmaceuticals, Inc. $(MIRA)$ has announced topline results from the single ascending dose portion of its Phase 1 clinical trial for its lead oral candidate, Ketamir-2. The study evaluated the safety, tolerability, and pharmacokinetics of the drug in healthy volunteers. Conducted in a randomized, placebo-controlled format, the trial involved 32 participants across four escalating dose cohorts. Key findings indicate that Ketamir-2 was safe and well tolerated across all dose levels, with no severe adverse effects observed. The drug exhibited rapid and predictable absorption, supporting once-daily dosing, and did not present the CNS side effects commonly associated with ketamine. These results, already presented, highlight Ketamir-2's potential as a non-addictive treatment option for neuropathic pain, with the company exploring strategic partnerships to advance its development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1076223) on September 22, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10